June 14, 2018
New OICR President and Scientific Director comments on breakthroughs in breast cancer T-cell immunotherapy
For the first time, a patient’s late-stage breast cancer has been successfully treated with T-cell immunotherapy. This cutting-edge approach, which is currently in clinical trials in the U.S., modified the patient’s naturally-occurring immune cells to fight her tumours that had spread throughout her body. The patient has been cancer free for the past two years and her remarkable tumour regression represents the potential impact of this new immunotherapeutic approach.
May 17, 2018
Combination of erectile dysfunction drugs and flu vaccine may help kill remaining cancer after surgery
A remarkable study led by Dr. Rebecca Auer from The Ottawa Hospital (TOH) shows that the unlikely combination of erectile dysfunction drugs and the flu vaccine may boost the immune system’s ability to clean up cancer cells left behind after surgery. This method demonstrated promising results in a mouse model, where it reduced the spread of cancer following surgery by 90 per cent. Now the approach will be tested in a first-of-its-kind clinical trial involving 24 patients at TOH.
January 4, 2018
Researchers at The Ottawa Hospital and the University of Ottawa have found that a combination of two immunotherapies – oncolytic viruses and checkpoint inhibitors – was successful in treating triple-negative breast cancer in mouse models. Triple-negative breast cancer is the most aggressive and hard-to-treat form of the disease.